Hillstream BioPharma to Host Virtual R&D Day to Showcase its Emerging Immuno-oncology Pipeline Targeting Drug-Resistant Cancers
February 06, 2023 07:00 ET
|
Hillstream BioPharma, Inc.
Quatramer-based HSB-1216 combined with anti-MUC1-C antibody designed to target cancer stem cells (CSCs) by inducing ferroptosis in drug resistant cancers HSB-1940, an anti-PD-1 Quatrabody™, is a...
Hillstream BioPharma Signs an Exclusive Option Agreement to Advance Next-Generation Anti-MUC1-C Agents for Drug Resistant Cancers
January 31, 2023 07:11 ET
|
Hillstream BioPharma, Inc.
Development expected to capitalize upon tumor targeting Quatramers™ MUC1-C could be effective against a number of drug resistant cancers such as metastatic triple negative breast cancer (TNBC),...
Hillstream BioPharma to Present at the Virtual Sidoti Micro-Cap Conference on January 18-19, 2023
January 17, 2023 11:29 ET
|
Hillstream BioPharma, Inc.
BRIDGEWATER, N.J., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) (“Hillstream” or the “Company”), a biotechnology company developing novel therapeutic candidates...
Hillstream BioPharma Announces Development of Proprietary Targeted Biologics, Knob Quatrabodies™ (HSB-1940) against PD-1, by combining Quatramers™ with OmniAb’s Picobodies™, via a Collaboration Agreement, against Novel, Unreachable and Undruggable Epitopes in High Value Validated Targets
December 01, 2022 08:47 ET
|
Hillstream BioPharma, Inc.
Collaboration allows Hillstream to enter the rapidly growing Immuno-oncology therapeutics market By capitalizing on the long half-life of tumor targeting Quatramers™ combined with OmniTaur™-derived...
Hillstream BioPharma to Present at the RHK Capital Disruptive Growth Conference on December 5-6, 2022
November 22, 2022 06:30 ET
|
Hillstream BioPharma, Inc.
BRIDGEWATER, N.J., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) (“Hillstream” or the “Company”), a biotechnology company developing novel therapeutic candidates...
Hillstream’s New Anti-Cancer Mechanism Quatramer-based Ferroptosis Inducer, HSB-1216 Abstract Available for Viewing at EORTC-NCI-AACR Symposium
October 18, 2022 08:47 ET
|
Hillstream BioPharma, Inc.
BRIDGEWATER, N.J., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (“Hillstream”), a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new...
Hillstream BioPharma, Inc. to Present at Upcoming Investor Conferences
October 06, 2022 08:47 ET
|
Hillstream BioPharma, Inc.
BRIDGEWATER, N.J., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) (“Hillstream” or the “Company”), a biotechnology company developing novel therapeutic candidates...
Hillstream BioPharma to Participate in the Fierce Biotech Summit on September 19-20
September 14, 2022 08:47 ET
|
Hillstream BioPharma, Inc.
BRIDGEWATER, N.J., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) (“Hillstream” or the “Company”), a biotechnology company developing novel therapeutic candidates...
Hillstream BioPharma to Attend the 12th Annual World Orphan Drug Congress USA on July 11-13
July 08, 2022 08:17 ET
|
Hillstream BioPharma, Inc.
BRIDGEWATER, N.J., July 08, 2022 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) (“Hillstream” or the “Company”), a biotechnology company developing novel therapeutic candidates...
Hillstream BioPharma Announces Collaboration with Sapien Biosciences in Cancer Treatments
June 27, 2022 08:27 ET
|
Hillstream BioPharma, Inc.
BRIDGEWATER, N.J., June 27, 2022 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) (“Hillstream” or the “Company”), a biotechnology company developing novel therapeutic candidates...